

Biochemical aspects of cystic fibrosis and kidney disease: A brief discussion

Durr e Sabih¹, Zahed Mahmood¹, Muhammad Jahangeer^{1*}, Naveed Munir¹, Areej Riasat¹, Shoukat Hussain¹.

¹Department of Biochemistry Government College University Faisalabad, Pakistan

*Corresponding email: rajahangeer@gcuf.edu.pk

Abstract

Cystic fibrosis is a recessive autosomal disease. A nosographic entity that considered lethal in childhood. In organs such as the hypothalamus, kidney, and bone, the protein is directly affected, where its malfunction is likely to imply linear delays in growth, delayed pubertal onset, modulation of bone density, and susceptibility to renal calculus, which may be present in CF and have been in use for years. Nevertheless, the most researched and recognized cause of renal wound is iatrogenic in CF patients due to the consumption by pulmonary exacerbation of large doses of aminoglycosides (3-5 mg/kg/dose). The rise in the incidence of CF nephrocalcinosis does not seem to be connected to an inherent renal issue. Among fact, chronic kidney disease (CKD) prevalence in CF patients looks to be at least twice as high with a double rise every 10 years impacting over 20% of individuals older than 55 years. There has been no substantial change in proteome content in the treatment of CFTR modulators. These data indicate that a re-regulating proteasome activities adapts CF cells to the CFTR deficiency and impairs autophagy and endosomal aiming.

Keywords: Cystic fibrosis transmembrane receptor, cystic fibrosis, kidney, chronic kidney disease, aminoglycosides

I. Introduction

In Caucasians, cystic fibrosis is a recessive autosomal disease. In clinical and basic research it considered an achievable and successful model in worldwide efforts. A nosographic entity that considered lethal in childhood. Over the decades, the CF clinical management improved, with patients predicted survival near 50 years in some areas (McColley, 2016), (Hurley et al., 2014). Adults make up the majority of patients in numerous countries and this trend is anticipated in next years (Burgel et al., 2015). CF has also been emerging as a disease that is more complex than previously thought, and the much-desired and much-welcomed improvement in disease control has come with significant clinical implications, such as an increased prevalence of malignancies and complications with renal and bone metabolism (Plant et al., 2013). CFTR the protein whose absence causes the illness, is expressed in numerous organs, although its complete tissue-specific role is still unknown. CFTR, an ABC protein (Gadsby et al., 2006) found in epithelial cells, has the characteristics of a anionic and chloride channel engaged in a number of physiological processes and is currently thought to act as a hub regulating many activities (Keiser & Engelhardt, 2011). The absence of functioning CFTR in the lower and higher airways, the gut, pancreas, and hepatic ducts is a key determinant in determining the degree of disease manifestation and, finally, death. In organs such as the hypothalamus, kidney, and bone, the protein is directly affected, where its

Sabih et al.

malfunction is likely to imply linear delays in growth (Padoan et al., 2013), delayed pubertal onset (Jin et al., 2006), modulation of bone density (Castellani & Asael, 2017), and susceptibility to renal calculus, which may be present in CF and have been in use for years, (Moryousef et al., 2021). In addition, CFTR is engaged in numerous natural immunity or immune response physiological processes which, in turn, have a role in lung disease progression. With elderly individuals reached very high rates of malignancies, the impairment of CFTR function has led to hypotheses that colonic and Leukemia risk might potentially be increased (Maisonneuve et al., 2013), (Billings et al., 2014). CFTR involves itself in the formation of a number of physiology mechanisms relating to natural immunity or immunological reactions. With elderly individuals reaching a reasonably high degree of malignancy it seems to raise the risk of colonic cancer and leukaemia as well. Lastly, CFTR dysfunction not only causes CF, it also appears in quite distinct diseases, such as secret diarrhoea and adult polycystic kidney disease, where the protein activity is more than normally occurring. Moreover, the failure of CFTR is not only causing CF but also appears to be causing quite distinct diseases, like secretory diarrhoea and polycystic adult kidney disease, where protection activity is higher than usual (Azimi, 2015). Renal dysfunction in CF may be linked to the underlying illness, comorbidity, and therapy received by patients. The CFTR genome is really also distributed in the kidneys, producing changes to the homeostasis, although nothing has been investigated on renal implication until now. Moreover, co-morbidity like diabetes may induce nephropathy. Nevertheless, the most researched and recognized cause of renal wound is iatrogenic in CF patients due to the consumption by pulmonary exacerbation of large doses of aminoglycosides (3-5 mg/kg/dose) (Chmiel et al., 2014). The renal excretion by glomerular filtration characterises aminoglycosides, which up to 15 percent are absorbed through a saturable mechanism into the proximal tube, so that dose-dependent action is taken once phenomena of cellular death have been surmounted. The therapeutic dose is comparable to the toxic dose in CF patients (Inkeretal., 2014), (Santoro et al., 2017). We anticipate that CKD is more common in the adult CF population than in the overall adult Scandinavian community, and that the most relevant features of individuals with CKD are CFRD and longer cumulative intravenous usage of potentially nephrotoxic antibiotics. Progress in CF therapy has enhanced life expectancy, and other previously unexpected illnesses are now found in CF patients. The aim of this review is the confirmation and screening of renal dysfunction, CFTR role in kidney and treatment with aminoglycoside and tobramycin

II. Confirmation and screening of renal dysfunction

All have a role in determining renal function in the blood stream, glomerular filtration and tubular resorbent capacities. The assessment of kidney function is confined, in humans, to the measure of GFR, renal blood flow and proteinuria and creatinine clearance determined from different equations. Although GFR is the largest clinical test for kidney function, it has its limits and significantly corresponds to both clinical severity and anomalies of renal function. The clearance of suitable Filters that are no longer reabsorbed metabolized or secreted by the kidney (e.g. Inulin, Cr-EDTA, iohexol, ⁹⁹Tc-DTPA) cannot be assessed directly and must be estimated indirectly. Testing these markings with intravenous infusions, however, is costly and time intensive and needs accurate collection of samples. Different CF sufferers do not have normal or regular serum creatinine levels, which complicates their evaluation. In GFR's early identification of renal disease, less than 30 percent of nephrons can cease working before changing GFR, while others increase their filtration rate and modify them (Griffin et al., 2018).

GFR will only decrease with each loss of renal tissue. Indirect techniques based on the clearance by the kidney of physiological product were identified because of the

difficulties of direct measurement of GFR. The test is called creatinine clearance (CCL). Creatinine, a disruptive muscle product, is generated predictably in stable people and reabsorbed by the kidney tubules only slightly. Although, given that CCL is measured in a precise urinary system, it is prone to adult and young children to mistake, a variety of formulae have been developed to estimate the CCL on the basis of serum creatinine, muscle weight and physical constants (eCCL). Formulas such as the Renal Disease (aMDRD) Equations and the Cockcroft-Gault Formula (CGF) (Chicco & Jurman, 2020) are extensively used and promoted for patients with CF. On the other hand, even when the formulas are simple to apply in everyday practise, when serum creatinine is variable, they over-estimate CCL and hence GFR when creatinine increases and vice versa they are not trustworthy (Yee et al., 2018). Their validation has been deficient in CF, and this failure to validate is particularly significant as many CF patients are in a hypermetabolic condition and they have reduced muscle mass and a restricted ability to exercise (Ruf et al., 2019). Some experimental data released by health department they compared 74 adults with normal blood creatinine range, no past history of kidney disease and BMI matches at 29 age. Compared to eCCL with different formulae, the measured creatinine clearance was all less favourable (including popular CGF and AMDRD estimations) than controls and substantially overestimated renal function in CF patients with decreased CCL (b80mL/min) (Crawford et al., 2017). Medicines like aminoglycosides can damage the tubes proximately, leading to acute tubular necrosis, leading to electrolyte leak from a deficiency in urine concentrations and the increased urinary excretion of specific tubular enzymes (Saad et al., 2020). Therefore, throughout the past 40 years, the assessment of urine enzymes as non-invasive indicators of renal tubular injury has been focused. They may also be helpful instruments for the early diagnose and reflect subclinical toxicity, and might play a key role in the screening of early renal impairment before traditional laboratory testing is rendered ruinous. They might still suggest initial damage to tubular lysosomes (N-acetyl- β -D-glucose-aminidase [NAG]) and brush border due to location (alanine amino-peptidase [AAP]). The increase in AAP following IV tobramycin has been observed by increased urine NAG release during aminoglycosis treatment IV in patients with CF, (Mohkam & Ghafari, 2015) and 1 research. Acute kidney insult indicators are regarded other markers such as neutrophil gelatinase-associated lipocaline (NGAL) and kidney injury molecule 1 (KIM-1) (Schrezenmeier et al, 2017), (Xu et al., 2015). Unfortunately the NGAL is also manufactured to prevent its usage in the CF disease, in response to injured epithelial lung cells (Guo et al., 2020). Recent urine KIM-1 interests as an indicator for renal necrosis and regeneration have not been extensively assessed and CF usage trials have not been conducted. Cystatin C (Lamb, 2015) is a novel protein used to evaluate renal function within the last decade; serum concentration is largely determined by glomerular filtration, making it an endogenous marker helpful for the assessment before metabolism by a proximal tubule. On the other hand, the results of the small number of studies in CF have not been fully evaluated (Wallace et al., 2020) and the superiority of this measure (Sorkhi et al., 2018) has been indicated, but 47 adult and pediature patients have found no statistical benefits in their studies over any alternative method of estimation of renal function and more sufficiently powdered.

III. Acute renal failure and CF

There are a number of causes for the risk of ARF in persons with CF. The deficiency in salt transport leads patients with CF to lose of salt and hence fluid imbalance and dehydration (Fuštik et al., 2018). The impact of the CFTR failure on

pancreas functions and architecture in a significant percentage of elderly people with CF results in severe hypoinsulinemia, again causing fluid balance problems and long-term possibility of diabetic kidney damage (Kelsey et Al., 2019) (Dupont, 2017). In addition, these people are exposed to a huge quantity of chemotherapeutic medications potentially nephrotoxic as a group. Our study however, since most patients were kids, is predicted to raise the incidence risks of ARF in the older age group with an increased cumulative exposure to potential nephrotoxic therapies and cystic fibrosis related diabetes (Just 3 in 18 years). Our cystic fibrosis facility has received a cumulative intravenous dosage of more than 300 g of aminoglycoside tobramycin. In order to corroborate this finding, higher rates of reaction from the centers of pediatrics to the survey may be indicated.

3.1 The function of CFTR in the renal

Despite the fact that salt transport is a major problem in CF, patients with the disease appear to have normal renal function. Despite the fact that the CFTR gene is abundantly expressed in the kidney, particularly in the nephron, it appears to be redundant at this site. Using a recombinant CFTR mouse-knockout model, scientists have found that CFTR deficiency does not impact the capacity of the kidney to regulate the salt balance and fluid but involves alternative salt and fluid channels for transportation. CFTR appears also to be an important modulator of fluid release into cysts in autosomal recessive polycystic kidney illness (Jouret & Devuyt, 2020). A protein encoding gene, the CFTR, which is trucked across the cell and places in the apical membrane as the chloride channel, encodes the cystic fibrosis (CF) gene.




Figure.1

The rise in the incidence of CF nephrocalcinosis does not seem to be connected to an inherent renal issue (Nazzal et al., 2016). The Cl-Channel for Cystic Fibrosis is expressed in all segments of the nephron. Although CFTR mutations are not associated with substantial kidney function abnormalities, kidney excretion of the drugs in the same way as concentrate and dilute urine and eliminate salt load in the kidney is changed in cystic fibrosis. . Whether these changes in renal function are attributable to reduced extracellular fluid volume induced by excessive sweat and faeces NaCl loss or due to inherent renal function defects that are caused by CFTR mutations is not apparent. There is much evidence that CFTR is instrumental in adjusting the cluster secretion by the distal tubule, major tube cells and the inner

medullary pipe (IMCD). In polycystic kidneys in cyst-lumens, CFTR is also vital for Cl⁻ Secretion and helps grow the cyst. Within certain situations, the electrochemical gradient of Cl⁻ will assist the Cl⁻ absorption through CFTR Cl channels if absorption across the apical membrane of main cells inside the CCD is increased and the apical membrane potential depolarized. A CFTR channel can be triggered by 3.5" cAMP and also by the Na channel epithelial (ENaC) and K⁺ channel secretory (ROMK2) for the transportation of both Na⁺ and K⁺ throughout the CCD channel acidification, protein processing, protein trade (PTS), ATP secretion, and the control. The excretion of the kidneys of Na⁺ and K⁺ can therefore be controlled by CFTR. The most common CFTR mutation is the delta F508, which leads to improper CFTR folding to the degraded reticular endoplasm. Therefore, in most people CF is a trafficking disease. Therefore, the intracellular CFTR trafficking in the kidney is not known. We have created an alive cell model in preliminary experiments to examine in-cell trafficking in renal-epithelial cells in CFTR and F508-CFTR. Our ultimate objective is to clear up intracellular trafficking in CFTR and discover treatment options for restore normal functioning of renal cells in CF and inhibit CFTR-mediated cl⁻ secretion in polycystic kidneys in cysts (Li et al., 2018)




Figure.2: The cystic fibrosis defect. A CFTR mutation inhibits the secretion of Cl⁻ and uncontrolled Na⁺ absorption leads to dehydration of ASL and a poor clearance of the mucosa.

3.2 Proteostasis dysregulation

Increased proteasomal subunit levels (proteasome subunit 6 protein) were seen in CF exosomes, and proteasomal gene enrichment in general, which indicated upregulated proteasomal pathways in the urinary tract of CF. In numerous additional CF organs, upregulation of proteasome subunits was also found, including the lung as an adaptability mechanism for recovering the excess of misfolded proteins F508del-CFTR (Fraser-Pitt & O'Neil 2015). It contrasts with ESCRT Proteins, an important protein mechanism for the destruction of misplaced proteins, which includes membrane-bound F508del-CFTR, by polyubiquitination at the endosomes. A deficient autophagy, as earlier documented in epithelial F508del respiratory cells, is indicated by the downregulations of proteins involving the ripening of phagosomes,

Sabih et al.

such as RAB-34 and RAB-20 (Esposito et al., 2016). Interestingly enough, the suggested mechanism for deficient autophagy in respiratory epithelial cells includes the buildup of transglutaminases (TGMs) cross-linking Beclin-1 to a significant autophagosomal protein which reduces autophagosome formation (Bodas & Vij 2019). This hypothesis is supported by an increase in TGM1 and TGM3 expression in this study. Degradation of the proteasome, delivery of the endosomal and autophagal pathways with ubiquitin marked proteins are closely linked and imbalance can lead to the buildup of misfolded proteins and cellular dysfunction. These exosomal proteomic findings demonstrate that cystic fibrosis renal cells adapt to the CFTR deficit, but that endosomal and autophagy targeting are at a disadvantage, as is seen in the pulmonary cell. Abnormal protein accumulation should lead to harm to the tubular cell along with time. As proximal dysfunction of the tubules proceeds slowly to interstitial tubular injuries, this would impact only long-term renal function. Among fact, chronic kidney disease (CKD) prevalence in CF patients looks to be at least twice as high with a double rise every 10 years impacting over 20% of individuals older than 55 years (Downes et al., 2015)

3.3 Tissue Repair Dysregulation and a Potential Pro-Aging CF Disease Signature in Urinary Exosomes

A tyrosine kinase receptor EGFR growth factor epidermal receptor whose binding induces many inflammatory process, proliferation of cell includes, oxidation process, signal transduction of downstream and regulation of extracellular matrix all are involved in renal damage and was the ,most upregulated protein in our exosomal proteomic data set (Rayego-Mateos et al., 2018). As a result, elevated EGFR may cause kidney injury via a variety of distinct signalling pathways. First, a reduction in urine exosomal concentrations of S-transferasis glutathione and superoxide dismutase (SOD) implies an imbalance in antioxidant response. These proteins involve electrophilic and superoxid O₂ – detoxification and the antioxidant deficiency is reduced.

Secondly, we noticed decreased urinary exosome expression of klotho. This is the first finding of a possible CF kidney klotho deficit. Downregulation of klothos is a known tools for improving the cell senescence of oxidative stress and consequent apoptose by lowering the SOD response (Lim et al., 2017) (Zou et al., 2018). Since Klotho has the kidney defence ability (Morales et al. 1996, for example) it should promote chronic renal illness through improper tissue healing and poor damage protection. The elevated amount of casapase 14, a protein that is implicated in apoptosis and prelamin A/C in CF exosomes, as accumulation of lamina proteins in different neurodegenerative illnesses (Jiang & Ji 2018), also suggests this "accelerated ageing" problem (Le Dour et al., 2017). Our findings also demonstrated that proteins and gene sets in urine exosomal matrisomes were consistently downregulated. The findings are seen by reduced expression of a significant number of genes in the cultures of respiratory epithelial cells, connected with connective tissue or extracellular space diseases (Chaudhary et al. 2019). An extremely dynamic arrangement which interacts with cells to control differentiation and migration of tissue injury repair. The aberrant tissue restructure in the CF cells could thus be indicated by decreased matrisom proteins and gene expression in CF urine exosome.

3.4 There is no proof of CFTR modulators' strong protection modulation

No significant changes in proteomic urine exosome content were made in treatment with Orkambi® or Symdeko®. Our findings contrasts with prior transcriptome studies that have found 36 genes that have significantly changed following Orkambi® therapy. While this is a small genomic number that suggests that these medicines could only have very limited transcription effects, the result shows changes in the relevant pathways, such as normalisation of protein synthesis, lower cell-death genes expression, and changes in oxidative phosphorylation in clinical

respondents, mitochondrial signalling function, eIF2 and IL-17. This discrepancy may be the result of the poor reverse renal phenotype of this CFTR modulator combination treatment. In addition, tubulointerstitial injury could not be eliminated from the therapy of CFTR modulators because of prior intravenous aminoglycosides. This, however, involves a single patient in our data set who has been treated regularly with intravenous tobramycin and this should not be the principal cause (Gauthier et al., 2020)

3.5 Other renal problems in CF

In the population of CF, there are rising evidence of various renal diseases, notwithstanding the difficulties associated with evaluating renal function in CF and nephrotoxic medication concerns. These are briefly shown below.

3.5.1 Nephrolithiasis

Low-urinary volumes related with salt depletion and dehydration, hyper oxaluria, hyperuricosuria and hypercalciuria occur in all CF and are associated with increased nephrolithiasis and nephrocalcinosis in 90% of autopsies. Hypercalciuria is related with furosemide and prednisolone and the protracted stagnation episodes that can happen in CF result in hypercalcemia and hypercalciuria. Repetitive usage of antibiotics leads, of course, to the elimination of intestinal oxalate degrading bacteria like *Oxalobacter formigenes*, which are subsequently absorbed by the intestine with the subsequent re-excretion of oxalates through the kidney. The incidence of renal stones is up to 6%, as against 2% in healthy matching controls (Moryousef et al., 2021).

3.5.2 Amyloidosis

Secondary amyloidosis caused by prolonged inflammation, causing nephrotic syndrome. While colchicine is likely to provide advantages most instances die poorly, with one year to come. It becomes more and more recognised in CF (Simpson et al., 2019).

3.5.3 IgA nephropathy

High amounts of IgA, presumably due to repeated infections and chronic inflammation, are detected in circulation in CF patients. The deposition of this elevated IgA in the kidney may produce more glomerulonephritis-led immunological activation. Furthermore, hepatic problems in CF affect the clearance of the immune complexity and raise the likelihood of renal deposition. A lot of autoimmune diseases are linked to IgA nephropathy: The prognosis of 25 percent mortality when CF is also present is poor. In CF patients up to 80% of the renal biopsy cases are the common cause of glomerulonephritis documented in CF patients (Saha et al., 2018).

3.6 Relevance of Acute Renal Failure in CF

Wilcock et al describe a much greater incidence risk of ARF than the non-CF population, as well as other news reports. The authors say that this can be a growing issue using local numbers, while earlier national data do not assess this. The incidence risk mentioned is most likely understated due to recruiting problems and case inspections. CF teams must consider these numbers and implement, for the sake of unintended kidney harm, "common sense" practices. The usage of aminoglycosides in warm temperatures and fast conditions should be monitored continuously (for instance, to alleviate a chest problem prior to general anesthesia). Sufferer should also prevent the use of extremely nephrotoxic medicines, like aminoglycosides, furosemide and ibuprofen simultaneously. If simultaneous usage is inevitable, careful surveillance is necessary. In view of the increased frequency of ARF in CF, it is essential that further formal renal function tests are carried out often to identify risky persons. Forms that are used for the determination of glomerular filtration rates using serum creatinine and other variables including weight, height and age. The Schwarz formula ($40 \times \text{height (cm)} / \text{serum creatinine}$

Sabih et al.

(mmol/l) is often employed; however, several equations exist, although none have been properly verified in CF. There have been concerns that these calculations might overstate the glomerular filtration rate in CF patients and that for those who are particularly sensitive more formal direct measurements may be necessary (for example, using ⁵¹CrEDTA or timed urine collections) (Wilcock et al., 2015)

3.7 CF with aminoglycosides acute renal failure

Inhaled drug preparations are more typically connected with intravenous therapy, however acute renal disorder (ARFs) can occur (Kaufman & Eliades, 2019). At adult patients with CF, 8 cases of intravenous tobramycin and 55 UK CF-center subsequent surveys were recorded in our centre (Somayaji et al., 2017), up to 10.5 ARF-/10,000 CF-patients per year. Few reports have been made from adult centers, however, indicating a significantly greater occurrence. In 88% (76% — gentamicin) of aminoglycoside cases at or during the previous week ARF was prescribed and in renal biopsies, 85% acute tubular necrosis was demonstrated (all having received gentamicin). Half renal dialysis was required and a full 92 percent recovery was observed. Gentamicin is more nephrotoxic than other aminoglycosides widely used in paediatric CF. Its structure (two amino sugars connected together with a hexose kernel) decreases absorption and potentiates tubular necrosis and ultimately renal disease due to their subsequent buildup (Krause et al., 2016) — not in individuals with CF.

3.8 Should our use of aminoglycosides be changed or reduced?

Aminoglycosides offer effective dosing-dedicated kills of the major pathogens *Pseudomonas aeruginosa* in CF (Serio et al., 2017). They work synergistically with a number of antibiotic classes including cephalosporins and are used to prevent the appearance of resistance. Only limited evidence to support this method could be identified in a systematic evaluation comparing single and combination IV treatments. This underlines the difficulty of evaluating long-term treatments with the short-term results which are usually accessible for systematic evaluations (Schmidt et al., 2018). Despite a lack of proof it is expected that aminoglycosides will continue to have a role in cf-armamentariums because of the increasing P-aeruginosa resistance and the development of epidemic strains. However, it should be taken into account new techniques. Combining intravenous cephalosporin aerosolised aminoglycoside may reduce the nephrotoxic potential, while preserving a degree of protection from resistance development. The equivalent efficacy was shown in a pilot trial on this strategy. ARF was, however, documented with isolated aerosolised tobramycin and renal work still needs to be closely watched Rotating antibiotic regimes can limit aminoglycoside exposure. Intravenous colistin (a polymixin) was used as an alternative to aminoglycosides and in adult patients, unless used with tobramycin, it was not connected with renal compromises. Many CF centres routinely treat chronic P aeruginosa infection 3 or 4 months intravenous antibiotics. Again, in view of the exposure levels of patients to possible nephrotoxic medications and the absence of proof, this could be an instruction for CF teams to reconsider (Simon, 2018). Sixteen out of 24 instances reported on gentamicin by Wilcock et al (Wilcock et al., 2015). The study group is conducting a more thorough case-control study to identify factors influencing the development of ARF; nonetheless, the use of intravenous gentamicin in the normal therapy of patients with CF cannot be supported by the data reported in this report. Alternative solutions should be used, and infrastructure should be put in place to enable this with adequate drug assimilation.

3.9 Tobramycin once every day

Tobramycin is the most extensively used intravenous aminoglycoside antibiotic in the UK for CF thoracic infection and has a lesser nephrotoxic risk than gentamicin. Currently, many CF units change to a dose scheme once daily. Once dosed daily, drug buildup is reduced and nephrotoxicity and ototoxicity risk may be reduced. The

TOPIC investigation alleviated fears about a decline in efficacy due to the quick elimination of CF renals (and increasing time below the minimal inhibitory concentration) (Smyth, 2016). This randomised controlled study was sufficient to show an equal effectiveness, without substantial harm, comparing once and three times daily regimes. An unsatisfactory later study showed the issue that *P. aeruginosa*'s resistance profile can be increased once daily dosage (Brockmeyer et al., 2020). A shift in practise is a major step forward toward a once daily dose system and CF teams must establish rigorous protocols and the precise dosing regimes. The best strategy to monitor once daily dose is still under discussion. Whether serum and renal function must be measured must be clarified (Dassner et al., 2017). The general influence on the incidence risk of ARF from this practical adjustment demands a careful assessment. In short, Bertenshaw and our colleagues gave us vital insights on an unusual but devastating CF complication. With these findings in mind, the CF teams should focus on their strategy for managing aminoglycoside drugs, especially.

IV. Conclusion

In Caucasians, cystic fibrosis is a recessive autosomal disease. Moreover, the failure of CFTR is not only causing CF but also appears to be causing quite distinct diseases, like secretory diarrhoea and polycystic adult kidney disease, where protection activity is higher than usual and the superiority of this measure has been indicated, but 47 adult and pediture patients have found no statistical benefits in their studies over any alternative method of estimation of renal function and more sufficiently powdered. The elevated amount of casapase 14, a protein that is implicated in apoptosis and prelamin A/C in CF exosomes, as accumulation of lamina proteins in different neurodegenerative illnesses, also suggests this "accelerated ageing" problem. The aberrant tissue restructure in the CF cells could thus be indicated by decreased matrisom proteins and gene expression in CF urine exosome. A shift in practise is a major step forward toward a once daily dose system and CF teams must establish rigorous protocols and the precise dosing regimes.

Reference

- Azimi, A. (2015). "Cystic fibrotics could survive cholera, choleraics could survive cystic fibrosis"; hypothesis that explores new horizons in treatment of cystic fibrosis. *Medical hypotheses*, 85(6), 715-717.
- Billings, J. L., Dunitz, J. M., McAllister, S., Herzog, T., Bobr, A., & Khoruts, A. (2014). Early colon screening of adult patients with cystic fibrosis reveals high incidence of adenomatous colon polyps. *Journal of clinical gastroenterology*, 48(9), e85-e88.
- Bodas, M., & Vij, N. (2019). Adapting proteostasis and autophagy for controlling the pathogenesis of cystic fibrosis lung disease. *Frontiers in pharmacology*, 10, 20.
- Burgel, P. R., Bellis, G., Olesen, H. V., Viviani, L., Zolin, A., Blasi, F., & Elborn, J. S. (2015). Future trends in cystic fibrosis demography in 34 European countries. *European Respiratory Journal*, 46(1), 133-141.
- Brockmeyer, J. M., Wise, R. T., Burgener, E. B., Milla, C., & Frymoyer, A. (2020). Area under the curve achievement of once daily tobramycin in children with cystic fibrosis during clinical care. *Pediatric Pulmonology*, 55(12), 3343-3350.

Sabih et al.

Castellani, C., & Assael, B. M. (2017). Cystic fibrosis: a clinical view. *Cellular and Molecular Life Sciences*, 74(1), 129-140.

Chaudhary, N., Ueno-Shuto, K., Ono, T., Ohira, Y., Watanabe, K., Nasu, A., ... & Shuto, T. (2019). Curcumin down-regulates toll-like receptor-2 gene expression and function in human cystic fibrosis bronchial epithelial cells. *Biological and Pharmaceutical Bulletin*, b18-00928.

Chicco, D., & Jurman, G. (2020). Machine learning can predict survival of patients with heart failure from serum creatinine and ejection fraction alone. *BMC medical informatics and decision making*, 20(1), 1-16.

Chmiel, J. F., Aksamit, T. R., Chotirmall, S. H., Dasenbrook, E. C., Elborn, J. S., LiPuma, J. J., ... & Ratjen, F. A. (2014). Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant *Staphylococcus aureus*, gram-negative bacteria, and multiple infections. *Annals of the American Thoracic Society*, 11(7), 1120-1129.

Crawford, T. C., Magruder, J. T., Grimm, J. C., Suarez-Pierre, A., Zhou, X., Ha, J. S., ... & Bush, E. L. (2017). Impaired renal function should not be a barrier to transplantation in patients with cystic fibrosis. *The Annals of thoracic surgery*, 104(4), 1231-1236.

Davis, C. A., Abramowsky, C. R., & Swinehart, G. (1984). Circulating immune complexes and the nephropathy of cystic fibrosis. *Human pathology*, 15(3), 244-247.

Downes, K. J., Patil, N. R., Rao, M. B., Koralkar, R., Harris, W. T., Clancy, J. P., ... & Askenazi, D. J. (2015). Risk factors for acute kidney injury during aminoglycoside therapy in patients with cystic fibrosis. *Pediatric Nephrology*, 30(10), 1879-1888.

Dupont, L. (2017). Lung transplantation in cystic fibrosis patients with difficult to treat lung infections. *Current opinion in pulmonary medicine*, 23(6), 574-579.

Krause, K. M., Serio, A. W., Kane, T. R., & Connolly, L. E. (2016). Aminoglycosides: an overview. *Cold Spring Harbor perspectives in medicine*, 6(6), a027029.

Simon, R. H. (2018). Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection. Available on <https://www.uptodate.com/contents/cystic-fibrosis-antibiotic-therapy-for-chronic-pulmonary-infection>. Accessed on 1st June.

Schmidt, M., Werbrouck, A., Verhaeghe, N., De Wachter, E., Simoens, S., Annemans, L., & Putman, K. (2018). Strategies for newborn screening for cystic fibrosis: A systematic review of health economic evaluations. *Journal of Cystic Fibrosis*, 17(3), 306-315.

Esposito, S., Tosco, A., Villella, V. R., Raia, V., Kroemer, G., & Maiuri, L. (2016). Manipulating proteostasis to repair the F508del-CFTR defect in cystic fibrosis. *Molecular and cellular pediatrics*, 3(1), 1-5.

Fraser-Pitt, D., & O'Neil, D. (2015). Cystic fibrosis—a multiorgan protein misfolding disease. *Future science OA*, 1(2).

Fuštik, S., Jakovska, T., & Plašeska-Karanfilska, D. (2018). Hyponatremic dehydration and metabolic alkalosis as dominant manifestation in cystic fibrosis

infants with mild phenotype—a case series. *Srpski arhiv za celokupno lekarstvo*, 146(9-10), 581-583.

Gadsby, D. C., Vergani, P., & Csanády, L. (2006). The ABC protein turned chloride channel whose failure causes cystic fibrosis. *Nature*, 440(7083), 477-483.

Gauthier, S., Pranke, I., Jung, V., Martignetti, L., Stoven, V., Nguyen-Khoa, T., ... & Sermet-Gaudelus, I. (2020). Urinary Exosomes of Patients with Cystic Fibrosis Unravel CFTR-Related Renal Disease. *International journal of molecular sciences*, 21(18), 6625.

Griffin, K. A., Polichnowski, A. J., & Bidani, A. K. (2018). Determinants of Hypertensive Renal Disease and Its Progression. In *Disorders of Blood Pressure Regulation* (pp. 465-478). Springer, Cham.

Guo, L., Zhu, B., Yuan, H., & Zhao, W. (2020). Evaluation of serum neutrophil gelatinase-associated lipocalin in older patients with chronic kidney disease. *Aging Medicine*, 3(1), 35-42.

Hoffmann, I. M., Rubin, B. K., Iskandar, S. S., Schechter, M. S., Nagaraj, S. K., & Bitzan, M. M. (2002). Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy. *Pediatric pulmonology*, 34(5), 375-377.

Hurley, M. N., McKeever, T. M., Prayle, A. P., Fogarty, A. W., & Smyth, A. R. (2014). Rate of improvement of CF life expectancy exceeds that of general population—observational death registration study. *Journal of Cystic Fibrosis*, 13(4), 410-415.

Inker, L. A., Astor, B. C., Fox, C. H., Isakova, T., Lash, J. P., Peralta, C. A., ... & Feldman, H. I. (2014). KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. *American Journal of Kidney Diseases*, 63(5), 713-735.

Serio, A. W., Magalhães, M. L., Blanchard, J. S., & Connolly, L. E. (2017). Aminoglycosides: Mechanisms of action and resistance. In *Antimicrobial drug resistance* (pp. 213-229). Springer, Cham.

Jiang, Y., & Ji, J. Y. (2018). Understanding lamin proteins and their roles in aging and cardiovascular diseases. *Life sciences*, 212, 20-29.

Jin, R., Hodges, C. A., Drumm, M. L., & Palmert, M. R. (2006). The cystic fibrosis transmembrane conductance regulator (Cftr) modulates the timing of puberty in mice. *Journal of Medical Genetics*, 43(6), e29-e29.

Jouret, F., & Devuyst, O. (2020). Targeting chloride transport in autosomal dominant polycystic kidney disease. *Cellular Signalling*, 109703.

Kaufman, A. C., & Eliades, S. J. (2019). Vestibulotoxicity in a patient without renal failure after inhaled tobramycin. *American journal of otolaryngology*, 40(3), 456-458.

Keiser, N. W., & Engelhardt, J. F. (2011). New animal models of cystic fibrosis: what are they teaching us?. *Current opinion in pulmonary medicine*, 17(6), 478.

Sabih et al.

Kelsey, R., Manderson Koivula, F. N., McClenaghan, N. H., & Kelly, C. (2019). Cystic Fibrosis-Related Diabetes: pathophysiology and therapeutic challenges. *Clinical Medicine Insights: Endocrinology and Diabetes*, *12*, 1179551419851770.

Lamb, E. J. (2015). Cystatin C: why clinical laboratories should be measuring it. *Annals of clinical biochemistry*, *52*(6), 709-711.

Le Dour, C., Wu, W., Béréziat, V., Capeau, J., Vigouroux, C., & Worman, H. J. (2017). Extracellular matrix remodeling and transforming growth factor- β signaling abnormalities induced by lamin A/C variants that cause lipodystrophy. *Journal of lipid research*, *58*(1), 151-163.

Li, M. S., Cowley, E. A., El Hiani, Y., & Linsdell, P. (2018). Functional organization of cytoplasmic portals controlling access to the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel pore. *Journal of Biological Chemistry*, *293*(15), 5649-5658.

Lim, S. W., Jin, L., Luo, K., Jin, J., Shin, Y. J., Hong, S. Y., & Yang, C. W. (2017). Klotho enhances FoxO3-mediated manganese superoxide dismutase expression by negatively regulating PI3K/AKT pathway during tacrolimus-induced oxidative stress. *Cell death & disease*, *8*(8), e2972-e2972.

Maisonneuve, P., Marshall, B. C., Knapp, E. A., & Lowenfels, A. B. (2013). Cancer risk in cystic fibrosis: a 20-year nationwide study from the United States. *Journal of the National Cancer Institute*, *105*(2), 122-129.

McColley, S. A. (2016). A safety evaluation of ivacaftor for the treatment of cystic fibrosis. *Expert opinion on drug safety*, *15*(5), 709-715.

Mohkam, M., & Ghafari, A. (2015). The Role of Urinary N-acetyl-beta-glucosaminidase in Diagnosis of Kidney Diseases. *Journal of Pediatric Nephrology*, *3*(3), 84-91.

Morales, M. M., Carroll, T. P., Morita, T., Schwiebert, E. M., Devuyst, O., Wilson, P. D., ... & Guggino, W. B. (1996). Both the wild type and a functional isoform of CFTR are expressed in kidney. *American Journal of Physiology-Renal Physiology*, *270*(6), F1038-F1048.

Moryousef, J., Kwong, J., Kishibe, T., & Ordon, M. (2021). Systematic Review of the Prevalence of Kidney Stones in Cystic Fibrosis. *Journal of Endourology*, (ja).

Moryousef, J., Kwong, J., Kishibe, T., & Ordon, M. (2021). Systematic Review of the Prevalence of Kidney Stones in Cystic Fibrosis. *Journal of Endourology*, (ja).

Mukherjee, R., Whitehouse, J., & Honeybourne, D. (2008). Renal impairment in cystic fibrosis. *Thorax*, *63*(5), 473-473.

Nazzal, L., Puri, S., & Goldfarb, D. S. (2016). Enteric hyperoxaluria: an important cause of end-stage kidney disease. *Nephrology Dialysis Transplantation*, *31*(3), 375-382.

Padoan, R., Blau, H., Marostica, A., Fuoti, M., Volpi, S., Pilotta, A., ... & Assael, B. M. (2013). Growth retardation and reduced growth hormone secretion in cystic

fibrosis. Clinical observations from three CF centers. *Journal of Cystic Fibrosis*, 12(2), 165-169.

Plant, B. J., Goss, C. H., Plant, W. D., & Bell, S. C. (2013). Management of comorbidities in older patients with cystic fibrosis. *The Lancet Respiratory Medicine*, 1(2), 164-174.

Rayego-Mateos, S., Rodrigues-Diez, R., Morgado-Pascual, J. L., Valentijn, F., Valdivielso, J. M., Goldschmeding, R., & Ruiz-Ortega, M. (2018). Role of epidermal growth factor receptor (EGFR) and its ligands in kidney inflammation and damage. *Mediators of inflammation*, 2018.

Ruf, K., Beer, M., Köstler, H., Weng, A. M., Neubauer, H., Klein, A., ... & Hebestreit, H. (2019). Size-adjusted muscle power and muscle metabolism in patients with cystic fibrosis are equal to healthy controls—a case control study. *BMC pulmonary medicine*, 19(1), 1-11.

Saad, A., Young, M. R., Studtmann, A. E., Autry, E. B., Schadler, A., Beckman, E. J., ... & Kuhn, R. J. (2020). Incidence of nephrotoxicity with prolonged aminoglycoside exposure in patients with cystic fibrosis. *Pediatric Pulmonology*, 55(12), 3384-3390.

Saha, M. K., Julian, B. A., Novak, J., & Rizk, D. V. (2018). Secondary IgA nephropathy. *Kidney international*, 94(4), 674-681.

Santoro, D., Postorino, A., Lucanto, C., Costa, S., Cristadoro, S., Pellegrino, S., ... & Bellinghieri, G. (2017). Cystic fibrosis: a risk condition for renal disease. *Journal of Renal Nutrition*, 27(6), 470-473.

Schrezenmeier, E. V., Barasch, J., Budde, K., Westhoff, T., & Schmidt-Ott, K. M. (2017). Biomarkers in acute kidney injury—pathophysiological basis and clinical performance. *Acta physiologica*, 219(3), 556-574..

Seto, S., Tsujimura, K., & Koide, Y. (2011). Rab GTPases regulating phagosome maturation are differentially recruited to mycobacterial phagosomes. *Traffic*, 12(4), 407-420.

Simpson, T., Elston, C., Macedo, P., & Perrin, F. (2019). Amyloidosis in cystic fibrosis. *Paediatric respiratory reviews*, 31, 32-34.

Smyth, A. (2016). Treatment of pulmonary exacerbations in cystic fibrosis—could do better?. *Paediatric respiratory reviews*, 20, 6-7.

Somayaji, R., Lam, J. C., Surette, M. G., Waddell, B., Rabin, H. R., Sibley, C. D., ... & Parkins, M. D. (2017). Long-term clinical outcomes of 'Prairie Epidemic Strain' *Pseudomonas aeruginosa* infection in adults with cystic fibrosis. *Thorax*, 72(4), 333-339.

Sorkhi, H., Behzadi, R., Joghtaei, N., Poornasrollah, M., & Bijani, A. (2018). Glomerular filtration rate determination by creatinine and cystatin-C in patients with acute pyelonephritis. *Caspian journal of internal medicine*, 9(3), 290.

Sabih et al.

Dassner, A. M., Sutherland, C., Giroto, J., & Nicolau, D. P. (2017). In vitro activity of ceftolozane/tazobactam alone or with an aminoglycoside against multi-drug-resistant *Pseudomonas aeruginosa* from pediatric cystic fibrosis patients. *Infectious diseases and therapy*, 6(1), 129-136.

Wallace, A., Price, A., Fleischer, E., Khoury, M., & Filler, G. (2020). Estimation of GFR in patients with cystic fibrosis: a cross-sectional study. *Canadian journal of kidney health and disease*, 7, 2054358119899312.

Wilcock, M. J., Ruddick, A., Gyi, K. M., & Hodson, M. E. (2015). Renal diseases in adults with cystic fibrosis: a 40 year single centre experience. *Journal of nephrology*, 28(5), 585-591.

Xu, Y., Xie, Y., Shao, X., Ni, Z., & Mou, S. (2015). L-FABP: A novel biomarker of kidney disease. *Clinica chimica acta*, 445, 85-90.

Yee, M. E., Lane, P. A., Archer, D. R., Joiner, C. H., Eckman, J. R., & Guasch, A. (2018). Losartan therapy decreases albuminuria with stable glomerular filtration and permselectivity in sickle cell anemia. *Blood Cells, Molecules, and Diseases*, 69, 65-70.

Zou, D., Wu, W., He, Y., Ma, S., & Gao, J. (2018). The role of klotho in chronic kidney disease. *BMC nephrology*, 19(1), 1-12.